View

The Study

Effects of Selenium Supplementation on Graves' Disease: A Systematic Review and Meta-Analysis

In simple terms

This study looked at many small experiments where some people took selenium pills and others didn’t. It found that selenium seemed to help lower some thyroid chemicals for a few months, but then the effect went away. It doesn’t prove selenium fixes Graves’ disease—it just shows a possible short-term link.

39%

Analysis score

39/ 100

Maximum 100 for a systematic review with meta-analysis.

Where the score came from

Reporting0
Methodology0
Publication100
Statistical77
Study type (basis of the score)
Systematic Review with Meta-Analysis
Level 1a - Systematic review of RCTs
What’s the bottom line?

Selenium pills temporarily help lower some thyroid hormones in people with Graves' disease who are already on medicine, but the effect doesn't last.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Reviews of RCTs (Meta-analyses)
Level 1a
39

39 / 100

Quality score

The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.

Can establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1The changes are real but short-lived and don't translate to feeling better, fewer relapses, or improved eyes.
  2. 2At 3–6 months: FT4 dropped by 0.86, FT3 by 0.34, TRAb dropped, TSH rose slightly.
  3. 3At 9 months: all levels returned to normal.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Evidence-based Complementary and Alternative Medicine : eCAM

Year

2018

Authors

Huijuan Zheng, Junping Wei, Liansheng Wang, Qiuhong Wang, Jinrong Zhao, Shuya Chen, Fan Wei

Open Access
37 citations
Analysis v5

Related Content

Claims (6)

Assertion

Taking selenium supplements is associated with lower levels of antibodies that attack the thyroid in people diagnosed with autoimmune thyroid disease.

Causal
Read analysis
Assertion

Taking selenium supplements at 100–300 micrograms per day for 3 to 6 months may lead to a small rise in thyroid-stimulating hormone levels in adults with Graves' disease who are on antithyroid drugs, but this change does not continue after 6 months.

Correlational
Read analysis
Assertion

There is no clear evidence that taking selenium supplements improves key outcomes for people with Graves' disease, such as reducing relapses, improving quality of life, or easing eye symptoms.

Descriptive
Read analysis
Assertion

In adults with Graves' disease taking antithyroid medication, taking selenium supplements at 100–300 μg per day for 3 to 6 months lowers levels of FT3 and FT4 hormones in the blood, but these reductions do not remain after 9 months of treatment.

Causal
Read analysis
Assertion

Taking selenium supplements daily at 100–300 micrograms for six months may lower levels of antibodies targeting the thyroid-stimulating hormone receptor in adults with Graves' disease who are on antithyroid drugs, but this reduction does not last beyond nine months.

Correlational
Read analysis
Assertion

Taking selenium supplements does not keep thyroid hormone levels improved in people with Graves' disease beyond six months; after nine months, these levels return to what they were before treatment, even if supplementation continues.

Descriptive
Read analysis
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.